Information  X 
Enter a valid email address

YM BioSciences Inc. (YMB)

  Print      Mail a friend

Monday 17 November, 2008

YM BioSciences Inc.

Notice of YM Biosciences Annual and Special Mee...

Notice of YM Biosciences Annual and Special Meeting of Shareholders

    MISSISSAUGA, ON, Nov. 17 /CNW/ - YM BioSciences Inc. (NYSE Alternext
US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide, will hold its
Annual and Special Meeting of Shareholders on Thursday, November 20, 2008 at
4:00 p.m. EST.

    Where:      The Gallery
                TSX Broadcast & Conference Center
                The Exchange Tower
                130 King Street West
                Toronto, Ontario

    When:       November 20, 2008 at 4:00 p.m. EST

    Webcast:    A live audio webcast of the call will be available at
       Webcast attendees are welcome to
                listen in real-time or on-demand at their convenience. The
                webcast will be archived for 365 days. Please connect to this
                website at least 15 minutes prior to the conference call to
                ensure adequate time for any software download that may be
                needed to hear the webcast.

    The management proxy circular documents and annual financial documents
have been mailed to shareholders and are available online at and

    About YM BioSciences

    YM BioSciences Inc. is a company that identifies, develops and
commercializes differentiated products principally in the area of oncology for
patients worldwide. The Company is developing nimotuzumab, a humanized
monoclonal antibody, and AeroLEF(R), a proprietary, inhaled-delivery
composition of free and liposome-encapsulated fentanyl. Nimotuzumab is in
development targeting multiple tumour types in combination with radiation,
chemoradiation and chemotherapy. The drug, which is approved for marketing in
eight countries, is significantly differentiated from all other currently
marketed EGFR-targeting agents because of a remarkably benign side-effect
profile. In approximately 3,000 patients treated worldwide, to date, no Grade
III/IV rash has been reported and reports of any of the other side-effects
that are typical of EGFR-targeting molecules have been rare. AeroLEF(R) is in
development for the treatment of moderate to severe pain, including cancer
pain. The product completed a randomized trial in 2007 and is being prepared
for late-stage development internationally.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(R) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or

For further information: Thomas Fechtner, the Trout Group LLC, Tel. (646)
378-2931, Email: tfechtner(at); James Smith, the Equicom Group
Inc., Tel. (416) 815-0700 x 229, Email: jsmith(at); Nominated
Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050 6500